Leukocare, a Munich, Germany-based clinical-stage biotechnology company, closed a growth financing round of undisclosed amount.
The round was led by LifeCare Partners, with participation from a group of new investors and current shareholders. As part of the financing, Dr. Gerhard Ries, Managing Partner at LifeCare Partners, and Dr. Jean-Paul Prieels, an industry expert in the vaccine field, will join the supervisory board.
Led by Michael Scholl, CEO, Leukocare provides stabilizing and protecting formulation technologies for proteins and other biologics.
The company intends to use the funds to conduct market access activities for a number of development projects based on its Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.